Sugi Predict

Sugi Predict / Compounds / SCHEMBL201830

SCHEMBL201830

SCHEMBL201830

CCc1cccc2sc(N)nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ PDPK1 O15530 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ PDE10A Q9Y233 1/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MAPT P10636 3/20 0.44
▸ IDO1 P14902 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ HTR1A P08908 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ HTR2A P28223 1/20 0.43
▸ TLR8 Q9NR97 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL27691709 0.92 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL9722755 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL14531016 0.84 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL29236690 0.83 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL19859620 0.82 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL14531430 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL28244845 0.82 PDPK1 (0.61) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL11638058 0.82 LMNA (0.61) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL14532121 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A
SCHEMBL28161784 0.81 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2PDPK1LMNAPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 — — US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SPARCBIO LLC 2023-01-26 — — US disclosed
WO-2021219090-A1 QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN 北京泰德制药股份有限公司 (CN) 2021-11-04 — — WO disclosed
WO-2021219091-A2 QUINOXALINONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN 北京泰德制药股份有限公司 (CN) 2021-11-04 — — WO disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 — — US disclosed
CN-102008459-B Antibacterial agents BIOTA SCIENT MAN 2013-05-29 — — CN disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 — — US disclosed
US-20120122918-A1 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-05-17 — — US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 — — US disclosed
CN-101404989-B Antibacterial agent PROLYSIS LTD 2011-10-05 — — CN disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 — — EP disclosed
CN-102008459-A Antibacterial agents PROLYSIS LTD 2011-04-13 — — CN disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 — — US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 — — CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 — — EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122918-A1 ANTIBACTERIAL AGENTS ALK, ROS1, ARG1 ALDH1A1 787/4885SMN1; SMN2 3366/4885PDPK1 3839/4885
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 ALDH1A1 800/4885SMN1; SMN2 1208/4885PDPK1 4423/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 ALDH1A1 740/4885SMN1; SMN2 2959/4885PDPK1 4106/4885
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS ALDH1A1 2917/4885SMN1; SMN2 1518/4885PDPK1 837/4885
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS ALDH1A1 2350/4885SMN1; SMN2 2473/4885PDPK1 613/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 ALDH1A1 800/4885SMN1; SMN2 1208/4885PDPK1 4423/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 ALDH1A1 800/4885SMN1; SMN2 1208/4885PDPK1 4423/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS ALDH1A1 3208/4885SMN1; SMN2 3857/4885PDPK1 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.